Moleculin Biotech, Inc. Accrued Liabilities, Current
Moleculin Biotech, Inc. (MBRX) had Accrued Liabilities, Current of $4.98 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Liabilities, Current $4.98M.
- 2026-03-31: Accrued Liabilities, Current $3.39M.
- 2025-12-31: Accrued Liabilities, Current $3.35M.
- 2025-09-30: Accrued Liabilities, Current $3.57M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $4.98M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $3.39M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $3.35M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $3.57M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $4.19M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $4.19M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $3.33M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $3.04M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $2.91M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $3.30M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $4.32M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $1.88M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.42M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $3.09M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $2.72M 10-K · filed 2024-03-22 | |
| 2022-09-30 | $2.79M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.67M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $2.61M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $2.26M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $2.27M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.84M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $2.65M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $1.79M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $2.10M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $1.82M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $2.03M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $1.42M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $1.11M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.39M 10-Q · filed 2019-08-16 | |
| 2019-03-31 | $1.25M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $2.45M 10-K · filed 2020-03-19 | $2.30M 10-K · filed 2019-02-21 |
| 2018-09-30 | $1.82M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $1.84M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $766.00K 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $902.00K 10-K · filed 2019-02-21 | |
| 2016-12-31 | $650.00K 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |